NCT01147861 is a Phase 1 clinical trial of GSK256073 in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.

Who is sponsoring NCT01147861?

NCT01147861 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT01147861?

Interventions in NCT01147861: GSK256073, GSK256073, GSK256073, GSK256073, Placebo.

What condition does NCT01147861 study?

NCT01147861 studies Diabetes Mellitus, Type 2.

Is NCT01147861 still recruiting?

NCT01147861 is currently completed. Last updated 14 June 2017.

Last reviewed 2017-06-14 · How we verify

NCT01147861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

Completed Phase 1 Last updated 14 June 2017

What this trial tests

Phase 1 trial testing GSK256073 in Diabetes Mellitus, Type 2 in 39 participants. Completed in 7 September 2010.

Timeline

1 July 2010

Primary endpoint
7 September 2010

7 September 2010

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	39
Start date	1 July 2010
Primary completion	7 September 2010
Estimated completion	7 September 2010
Sites	4 locations across United States

Drugs / interventions tested

GSK256073 — full drug profile →
GSK256073 — full drug profile →
GSK256073 — full drug profile →
GSK256073 — full drug profile →
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 20 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to verify whether a significant decrease in glucose levels can be achieved with the HM74A agonist GSK256073 in type 2 diabetic patients. Several dose levels and a placebo will be evaluated in a three period crossover study with two active doses and one placebo dose per subject, in order to determine whether there is a dose that produces glucose lowering in the target population. In addition, this study will investigate the optimal dosing regimen for full manifestation of any metabolic effect of GSK256073 by comparing once a day versus twice a day regimens.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

GPCRs involved in metabolic diseases: pharmacotherapeutic development updates.
Jin C, Chen H, Xie L, Zhou Y, et al · · 2024 · cited 25× · PMID 38326623 · DOI 10.1038/s41401-023-01215-2

Verify or expand the search:

Other trials of GSK256073

Trials testing the same drug.

NCT00903617 — Study to Test GSK256073 in Patients With Dyslipidemia · Phase 2 · completed
NCT00808093 — Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01147861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 14 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01147861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing